ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT

ARK Investment Management LLC increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,872,721 shares of the biotechnology company’s stock after purchasing an additional 157,681 shares during the period. ARK Investment Management LLC owned 6.90% of Arcturus Therapeutics worth $34,514,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ARCT. Osaic Holdings Inc. increased its holdings in shares of Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares during the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA acquired a new stake in Arcturus Therapeutics during the third quarter worth $111,000. China Universal Asset Management Co. Ltd. raised its position in Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 2,313 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Arcturus Therapeutics in the 3rd quarter valued at $147,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ARCT. Roth Mkm began coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price objective on the stock. Piper Sandler reduced their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, HC Wainwright decreased their price target on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and an average price target of $28.89.

Arcturus Therapeutics News Roundup

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Pipeline progress: Arcturus outlined the launch of a 12‑week Phase II cystic fibrosis (CF) trial and said it expects regulatory clarity for ARCT‑810 in 2026 — a near‑term catalyst if milestones and timelines hold. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 Q4 and FY2025 results and pipeline progress
• Neutral Sentiment: Minor analyst tweak: Citigroup raised its price target from $7 to $8 but kept a “neutral” rating — a modest endorsement but not a strong near‑term buy signal. Citigroup raises ARCT price target to $8
• Neutral Sentiment: Reported short‑interest data in recent summaries appears erroneous (zero shares / NaN change) and is not a meaningful indicator of current positioning. No reliable short‑squeeze signal is evident from those entries.
• Negative Sentiment: Quarterly miss: ARCT reported Q4 EPS of ($1.03) vs. consensus ($0.92) and revenue of $7.2M vs. $14.32M expected — the revenue shortfall and wider loss are the main drivers of the pullback. ARCT reports Q4 loss, misses revenue estimates Market reaction and Q4 details
• Negative Sentiment: Analyst volatility: Piper Sandler cut its price target sharply from $72 to $25 (still “overweight”), increasing headline risk and uncertainty around valuation — a big downward revision that can weigh on sentiment despite the maintained rating. Piper Sandler lowers ARCT PT to $25
• Negative Sentiment: Market reaction: Coverage noted an immediate share drop after the weak revenue print; higher‑than‑average intraday volume suggests selling pressure as investors digest the miss. ARCT falls on weak quarterly revenue

Arcturus Therapeutics Trading Down 4.2%

Shares of NASDAQ ARCT opened at $7.58 on Thursday. The stock has a market cap of $215.35 million, a P/E ratio of -3.18 and a beta of 2.40. The business’s fifty day simple moving average is $7.29 and its 200-day simple moving average is $11.35. Arcturus Therapeutics Holdings Inc. has a 12-month low of $5.85 and a 12-month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $14.32 million. Arcturus Therapeutics had a negative return on equity of 28.63% and a negative net margin of 80.19%. On average, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.